Home › Sclerosing Cholangitis › NCT02137668

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Who can join

2 Weeks – 40 Years · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
* Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.

Exclusion Criteria:

* Patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.
* Females who are pregnant may not participate.

About the study

The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.

What is being tested

• Oral Vancomycin (drug)

Sponsor: Sacramento Pediatric Gastroenterology · Participants: 200 · Started: 2010-07

Contact the study team

Official record on ClinicalTrials.gov — NCT02137668

Locations in the U.S.

Conditions

• Sclerosing Cholangitis
• Biliary Atresia

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.